Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

By S. M. Turpin, Hayley T. Nicholls, D. Willmes, Arnaud Mourier, S. Brodesser, Claudia M. Wunderlich, J. Mauer, E. Xu, Philipp Hammerschmidt, H. Brönneke and 7 more. Cell Metabolism, 2014

623 citations recorded by the source corpus.

Subfields: Biochemistry, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/8a01a47d4699f5b6172f48a5fa919a6985674c84

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Ruben Garcia-Martin
2. R. Kahn
3. R. G. Ludwig
4. M. Mori
5. K. Ekroos
6. B. Brandao

Citations in the corpus

• Insulin Resistance: From Mechanisms to Therapeutic Strategies (2021, background): “Also, liver-specific knock out of ceramide synthase 6 (CerS6) decreased hepatic ceramide levels (especially C16:0 species), protected against HFD-induced obesity, and improved glucose tolerance [129].”
• Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol (2016, background): “mediate insulin resistance in mice.(11,12) In Caenorhabditis elegans, long-chain ceramides were pro-apoptotic, and very-long-chain ceramides were anti-apoptotic.”
• Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments (2023, background): “For example, overexpression of ceramide synthase 2 (CERS2), a catalyst for the synthesis of verylong-chain fatty acids (VLCFAs) in hepatocytes, enhances insulin signaling despite elevating the total level of ceramide (66), whereas the depletion of CERS2 in WAT and liver results in weight gain and de”
• Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease (2019, background): “The extent to which alterations in ceramide metabolism might be linked to alterations in exosome formation and release has not been studied, but altered ceramide metabolism is found in metabolic syndrome (Holland et al., 2011; Turpin et al., 2014).”
• Trends in insulin resistance: insights into mechanisms and therapeutic strategy (2022, background): “Likewise, C16-ceramides exist in higher concentrations in obese adipose tissue and are associated with hepatic IR.(180,181) Several lines of evidence suggest that circulating adiponectin is closely related to ceramide concentrations, wherein adiponectin increases ceramidase activity associated with ”